CB2 Receptor Agonists for Inflammation and Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic applications of cannabinoids are limited by their psychoactive effects, and there is a need for compounds that can modulate the CB2 receptor to treat inflammation and pain without the central nervous system effects associated with CB1 receptor activation.
Innovation Solution
Development of novel compounds that selectively bind to and modulate the CB2 receptor, acting as agonists to treat inflammation and pain by administering therapeutic amounts, thereby avoiding the psychoactive effects mediated by CB1 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are used to treat inflammation and pain, then therapeutic benefits are achieved, but psychoactive effects occur due to CB1 receptor activation
Solution Approach 1:
The invention segments the cannabinoid receptor system into two distinct targets: CB1 receptors in the central nervous system (responsible for psychoactive effects) and CB2 receptors in the immune system (responsible for anti-inflammatory and analgesic effects). By developing compounds that selectively target only CB2 receptors, the therapeutic benefits are retained while the harmful psychoactive effects are eliminated.
Solution Approach 2:
The invention applies local quality by creating compounds with selective affinity for CB2 receptors rather than CB1 receptors. This selectivity ensures that the pharmacological action is localized to immune system tissues where CB2 receptors are expressed, preventing activation of central nervous system CB1 receptors and thus avoiding psychoactive effects while maintaining anti-inflammatory and pain-relieving properties.
2Ease of operation
If CB1 receptors are activated to achieve central nervous system effects, then euphoric and CNS effects occur, but addiction and dependence result
Solution Approach 1:
The invention extracts the anti-inflammatory and analgesic functions from the broader cannabinoid pharmacological profile by specifically targeting CB2 receptors. This extraction separates the beneficial peripheral effects from the harmful central effects, allowing therapeutic application without the risk of addiction and dependence associated with CB1 activation.
3Reliability
If selective CB2 agonists are used to treat inflammation, then anti-inflammatory effects are achieved, but central nervous system impact must be minimized
Solution Approach 1:
The invention utilizes parameter changes in receptor selectivity, designing compounds with specific molecular structures that confer high affinity for CB2 receptors and low affinity for CB1 receptors. This parameter optimization ensures potent anti-inflammatory effects through CB2 activation while minimizing or eliminating any impact on the central nervous system.
Data Source
AI summary
Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.